Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-93.
作者信息
Vieira Matheus, Maalouf Georgina, Hasan Milena, Le Joncour Alexandre, Karkeni Esma, Idir Merwan, Amelin Damien, Salem Joe-Elie, Gougis Paul, Lacorte Jean-Marc, Biard Lucie, Benveniste Olivier, Cacoub Patrice, Saadoun David, Allenbach Yves
机构信息
Centre National de Références Maladies Autoimmunes et systémiques rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, 75013 Paris, France.
Cytometry and Biomarkers UTechS, Center for Translational Science, Institut Pasteur, Paris, France.
出版信息
Joint Bone Spine. 2021 Jan;88(1):105074. doi: 10.1016/j.jbspin.2020.09.006. Epub 2020 Sep 17.
Abstract
摘要
相似文献
1
Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-93.细胞因子谱作为2019冠状病毒病的一种预后工具。对Quartuccio等人发表于《关节与脊柱》（Joint Bone Spine）2020年第87卷第191 - 93页的“2019冠状病毒病治疗的紧急途径：靶向下游炎症以预防灾难性综合征”的评论
Joint Bone Spine. 2021 Jan;88(1):105074. doi: 10.1016/j.jbspin.2020.09.006. Epub 2020 Sep 17.
2
Answer to Vieira et al. "Cytokine profile as a prognostic tool in coronavirus disease 2019". Joint Bone Spine 2020. Doi:10.1016/j.jbspin.2020.09.006.对维埃拉等人《2019年冠状病毒病中细胞因子谱作为预后工具》一文的回应。《关节与脊柱》2020年。doi:10.1016/j.jbspin.2020.09.006
Joint Bone Spine. 2021 Jan;88(1):105076. doi: 10.1016/j.jbspin.2020.09.008. Epub 2020 Sep 18.
3
Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.新型冠状病毒-19（SARS-CoV-2）通过白细胞介素-1（IL-1）引起细胞因子风暴导致 COVID-19 的急性重症肺部炎症：一种有前途的抑制策略。
J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):1971-1975. doi: 10.23812/20-1-E.
4
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺，增加白细胞介素-1 水平，导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
5
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.严重急性呼吸综合征冠状病毒 2 感染：细胞因子在 COVID-19 疾病中的作用。
Cytokine Growth Factor Rev. 2020 Aug;54:62-75. doi: 10.1016/j.cytogfr.2020.06.001. Epub 2020 Jun 2.
6
Letter to the Editor in response to Chen et al. 2020.致编辑的信，回应陈等人 2020 年的文章。
Respir Res. 2020 Nov 30;21(1):315. doi: 10.1186/s12931-020-01548-0.
7
The Novel Coronavirus and Inflammation.新型冠状病毒与炎症。
Adv Exp Med Biol. 2021;1321:127-138. doi: 10.1007/978-3-030-59261-5_11.
8
Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the Caused by SARS-CoV-2?己酮可可碱和别嘌呤醇：预防 SARS-CoV-2 引起的疾病的潜在药物？
Curr Pharm Des. 2020;26(35):4515-4521. doi: 10.2174/1381612826666200811180232.
9
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.新型冠状病毒（COVI-19 或 SARS-CoV-2）诱导促炎细胞因子（IL-1 和 IL-6）和肺部炎症：抗炎策略。
J Biol Regul Homeost Agents. 2020;34(2):327-331. doi: 10.23812/CONTI-E.
10
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
引用本文的文献
1
The Anti-Arthritic Potential of the Ethanolic Extract of Benth. Leaves and Icetexane Dinor-Diterpenoid Fruticuline B.Benth. 叶乙醇提取物及异贝壳杉烷二降二萜弗鲁替林B的抗关节炎潜力
Pharmaceuticals (Basel). 2024 Sep 18;17(9):1226. doi: 10.3390/ph17091226.
2
Anti-inflammatory effects of dexamethasone in COVID-19 patients: Translational population PK/PD modeling and simulation.地塞米松在 COVID-19 患者中的抗炎作用：转化人群 PK/PD 建模与模拟。
Clin Transl Sci. 2023 Sep;16(9):1667-1679. doi: 10.1111/cts.13577. Epub 2023 Jul 5.
3
Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome.地塞米松在 LPS 刺激的大鼠抗炎和免疫调节作用的药代动力学/药效学建模：细胞因子释放综合征模型。
J Pharmacol Exp Ther. 2023 Mar;384(3):455-472. doi: 10.1124/jpet.122.001477. Epub 2023 Jan 11.
4
Post-COVID-19 Arthritis and Sacroiliitis: Natural History with Longitudinal Magnetic Resonance Imaging Study in Two Cases and Review of the Literature.新冠后关节炎和骶髂关节炎：两例纵向磁共振成像研究的自然病史及文献复习。
Viruses. 2021 Aug 6;13(8):1558. doi: 10.3390/v13081558.
5
Molecular Mechanisms of Palmitic Acid Augmentation in COVID-19 Pathologies.新冠病毒疾病中棕榈酸增加的分子机制
Int J Mol Sci. 2021 Jul 1;22(13):7127. doi: 10.3390/ijms22137127.
本文引用的文献
1
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
2
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
3
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.我们应该在 COVID-19 中刺激还是抑制免疫反应？细胞因子和抗细胞因子干预。
Autoimmun Rev. 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
4
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.2019冠状病毒病治疗的紧急途径：针对下游炎症以预防灾难性综合征。
Joint Bone Spine. 2020 May;87(3):191-193. doi: 10.1016/j.jbspin.2020.03.011.
5
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
6
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.武汉成人 COVID-19 住院患者严重程度和死亡率的危险因素。
J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.
7
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
8
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件